ClinicalPath (formerly Via Oncology) Publications
Adelson K, et al. Effects of rising drug costs on efforts to control overall cost at a large academic cancer center.
[Abstract] J Clin Oncol 37, 2019 (suppl 27; abstr 2)
Rodríguez-Lopéz JL, Ling DC, Heron DE, Beriwal S. Lag Time Between Evidence and Guidelines: Can Clinical Pathways Bridge the Gap?
[Article] JOP. December 2018:JOP.18.00430
Mason C et al. Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non–Small Cell Lung Cancer Treatment Setting.
[Manuscript] J Clin Pathways 2017 4(1):49-54
Page R et al. Expanding indications of existing drugs and associated costs under risk reimbursement models.
[Abstract] J Clin Oncol 35, 2017 (suppl; abstr e18306)
Ellis PG et al. Using clinical pathways to understand biomarker testing patterns.
[Abstract] J Clin Oncol 35, 2017 (suppl; abstr e18189)
Cost and survival analysis before and after implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer.
[Article] J Oncol Pract. 2017 Apr;13(4):e346-e352
Ellis PG, O’Neil BH, Earle MF, et al. Clinical pathways: management of quality and cost in oncology networks in the metastatic colorectal cancer setting.
[Article] J Oncol Pract. 2017 Apr 5.
Gebhardt BJ et al. Peer review process for implementation of clinical pathways (CP): Does it improve compliance?
[Abstract] Pract Radiat Oncol. 2017 Jan 19. pii: S1879-8500(17)30006-1. doi: 10.1016/j.prro.2017.01.006.
Ellis PG et al. Impact of varying approaches used to compare costs between drug regimens.
[Abstract] J Clin Oncol 34, 2016 (suppl; abstr e18262)
Friedland D et al. Evaluating the impact of Via Pathways (VP) on the adoption of changing treatment paradigms in metastatic hormone-sensitive prostate cancer (mHSPC).
[Abstract] J Clin Oncol 34, 2016 (suppl; abstr e16510)
McCutcheon S et al. Frequency of efficacy, toxicity and cost as the deciding factor when determining clinical pathways
[Abstract] J Clin Oncol 34, 2016 (suppl; abstr e18169)
Ellis PG et al. Pathways Clinical Decision Support for Appropriate Use of Key Biomarkers.
[Article] JOP May 24, 2016 JOPR010546
Ellis PG, Weese JL. Clinical pathways as a platform to support clinical research.
[Abstract] [Poster] Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, 2016 (ABSTR 2594)
Shamah CJ, Saphner TJ. Effect on clinical trial participation by integration of a clinical pathway program into an electronic health record (EHR).
[Abstract] [Poster] J Clin Oncol 34, 2016 (suppl 7S; abstr 167)
Shamah CJ et al. Integration of a clinical pathways software into an EHR in a large, multisite, hospital-affiliated community oncology setting.
[Abstract] [Poster] J Clin Oncol 34, 2016 (suppl 7S; abstr 129)
Insights From Building a New National Cancer Institute Community Oncology Research Program Site
[Article] J Clin Oncol 34, 2016 (suppl; abstr 6613)
Heron DE et al. The standardization of skin cancer treatment recommendations through the analysis of clinical pathways data and an evidence-based, physician-driven committee process.
[Abstract] [Poster] J Clin Oncol 34, 2016 (suppl 7S; abstr 147)